New combo vaccine for infants shows promise in early trial
NCT ID NCT02140047
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new vaccine called MT-2301, which protects against Haemophilus influenzae type b (Hib), given together with the standard DPT-IPV vaccine (which protects against diphtheria, pertussis, tetanus, and polio). The trial involved 154 healthy infants aged 2 to 7 months. Researchers compared two doses of MT-2301 against an existing Hib vaccine (ActHIB) to see how well they triggered protective antibodies and whether they were safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Haemophilus b conjugate vaccine (MT-2301) combined with DPT-IPV vaccine
- What this could lead to
- If successful, this could lead to a new combination vaccine that protects infants against Hib disease, diphtheria, pertussis, tetanus, and polio with fewer injections.
- What could go wrong
- This is a Phase 2 trial with 154 participants, so results are preliminary. The new vaccine may not be as effective or safe as the existing vaccine (ActHIB).
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAEMOPHILUS INFLUENZA TYPE B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Investigational site
Fukuoka, Fukuoka, Japan